Literature DB >> 3580269

Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer.

J R Masters, R S Camplejohn, R R Millis, R D Rubens.   

Abstract

The relationships between response to chemotherapy of advanced breast cancer and the histological type, grade, elastosis content and DNA ploidy of the primary tumours were examined using paraffin-embedded tissue derived from 125 patients. Higher response rates were seen amongst tumours with a high elastosis content and those that were diploid. However, selection of patients with advanced breast cancer for chemotherapy will not be assisted significantly by an assessment of these features in the primary tumour.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3580269      PMCID： PMC2001690          DOI： 10.1038/bjc.1987.89

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Histological grade and response to endocrine therapy in breast cancer.

Authors:  R R Millis; R D Rubens; J R Masters; M J Minton
Journal:  Lancet       Date:  1981-07-11       Impact factor: 79.321

2.  Comparison of DNA flow cytometry from fresh and paraffin embedded samples of non-Hodgkin's lymphoma.

Authors:  R S Camplejohn; J C Macartney
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

3.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; R D Rubens; P P Carbone; J C Heuson; S Kumaoka; A Segaloff
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

4.  Estrogen receptor status of advanced breast cancer immediately before chemotherapy does not predict for response.

Authors:  J F Stewart; J L Hayward; R D Rubens; R J King
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Clinical and biological significance of aneuploidy in human tumours.

Authors:  M L Friedlander; D W Hedley; I W Taylor
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

7.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

8.  Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer.

Authors:  R Steiner; J F Stewart; B M Cantwell; M J Minton; R K Knight; R D Rubens
Journal:  Eur J Cancer Clin Oncol       Date:  1983-11

9.  Response to endocrine therapy and breast cancer differentiation.

Authors:  J R Masters; R R Millis; R D Rubens
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

10.  Elastosis and response to endocrine therapy in human breast cancer.

Authors:  J R Masters; R R Millis; R J King; R D Rubens
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640
View more
  10 in total

1.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Alzheimer disease.

Authors:  David S Knopman; Helene Amieva; Ronald C Petersen; Gäel Chételat; David M Holtzman; Bradley T Hyman; Ralph A Nixon; David T Jones
Journal:  Nat Rev Dis Primers       Date:  2021-05-13       Impact factor: 52.329

Review 3.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

4.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

5.  Paragangliomas: neuroendocrine features and cytometric DNA distribution patterns. A clinico-pathological study of 22 cases.

Authors:  R Jovanovic; G W Hacker; U G Falkmer; S Falkmer; L Mendel; A H Graf; A Höög; V Kanjuh; C Silfverswärd; L Grimelius
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

6.  DNA index, S-phase fraction, histological grade and prognosis in breast cancer.

Authors:  S M O'Reilly; R S Camplejohn; D M Barnes; R R Millis; D Allen; R D Rubens; M A Richards
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

7.  Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer.

Authors:  P Kronqvist; T Kuopio; P Jalava; Y Collan
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

8.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Authors:  T A Järvinen; K Holli; T Kuukasjärvi; J J Isola
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.

Authors:  R S Camplejohn; C M Ash; C E Gillett; B Raikundalia; D M Barnes; W M Gregory; M A Richards; R R Millis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

10.  Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Authors:  P Hietanen; C Blomqvist; V M Wasenius; E Niskanen; K Franssila; S Nordling
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.